首页> Diabetes, obesity & metabolism.> iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study

导出原文传递

翻译打印收藏纠错

第一作者： Nicola Morea

作者： Nicola Morea ^[1] ; Ravi Retnakaran ; Josep Vidal ; Vanita R.Aroda ; Minzhi Liu ; Aramesh Saremi ; Francesco Giorgino

作者单位： University of Bari Aldo Moro, Bari, Italy ^[1]

关键词 basal insulin GLP-1 analogue phase III study type 2 diabetes

发布时间 2021-06-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Diabetes, obesity & metabolism.

2020年22卷9期

1683-1689页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Diabetes, obesity & metabolism.

2020年22卷9期

1683-1689页

检索历史清除

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study

Diabetes, obesity & metabolism.

相似文献

同项目论文

Diabetes, obesity & metabolism.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study

Diabetes, obesity & metabolism.

相似文献

同项目论文

Diabetes, obesity & metabolism.

相关期刊

检索历史清除